Figures & data
Table 1 The Medical Products Agency: Swedish recommendations for the treatment of children with hemodynamically significant congenital heart disease with palivizumab
Table 2 Condensed description of algorithmTable Footnote*
Table 3 Children with hemodynamically significant congenital heart disease identified by the proposed algorithm (yearly prevalence per 1,000 live born)
Table 4 Distribution of children in studied interpretation groups and distribution of children with chromosomal aberrations